

Store at  
-20C  
#65707**VWF (D8L8G) XP<sup>®</sup> Rabbit mAb**

**Orders:** 877-616-CELL (2355)  
orders@cellsignal.com

**Support:** 877-678-TECH (8324)

**Web:** info@cellsignal.com  
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

**For Research Use Only. Not for Use in Diagnostic Procedures.**

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IP, IHC-P	H	Endogenous	310, 460	Rabbit IgG	#P04275	7450

**Product Usage Information****Application**

Western Blotting  
Immunoprecipitation  
Immunohistochemistry (Paraffin)

**Dilution**

1:1000  
1:50  
1:500

**Storage**

For a carrier free (BSA and azide free) version of this product see product #39413.

**Specificity/Sensitivity**

VWF (D8L8G) XP<sup>®</sup> Rabbit mAb recognizes endogenous levels of total VWF protein. This antibody recognizes both the VWF precursor and mature VWF.

**Source / Purification**

Monoclonal antibody is produced by immunizing animals with recombinant human VWF protein.

**Background**

VWF (Von Willebrand factor) is a multimeric plasma glycoprotein that promotes adhesion of platelets to sites of vascular injury (1). Mature circulating VWF is made up of disulfide-bonded multimers that are in a complex with factor VIII (2). VWF is stored in secretory Weibel-Palade bodies in endothelial cells (3,4). It is synthesized as a large precursor protein and undergoes extensive posttranslational modifications including dimerization in the endoplasmic reticulum followed by cleavage of the pro-peptide and multimerization in the Golgi apparatus (3,4). VWF is important in hemostasis, and genetic defects in the structure and modification of VWF can cause von Willebrand disease (VWD), the most common congenital bleeding disorder in humans (5). Alternatively, increased levels of VWF have been shown to be involved in acute coronary thrombosis and are a clinical risk marker for atherosclerosis (6). VWF has also been shown to have a role in inflammation, functioning as an adhesive site for a variety of leukocyte subsets (7). Through siRNA experiments and the use VWF-deficient mice, it has also been shown that VWF regulates angiogenesis (8).

**Background References**

1. Tschopp, T.B. et al. (1974) *J Lab Clin Med* 83, 296-300.
2. Hoyer, L.W. and Shainoff, J.R. (1980) *Blood* 55, 1056-9.
3. Jaffe, E.A. et al. (1974) *Proc Natl Acad Sci U S A* 71, 1906-9.
4. Wagner, D.D. et al. (1986) *J Cell Biol* 102, 1320-4.
5. Sadler, J.E. (2005) *Annu Rev Med* 56, 173-91.
6. Lip, G.Y. and Blann, A. (1997) *Cardiovasc Res* 34, 255-65.
7. Pendu, R. et al. (2006) *Blood* 108, 3746-52.
8. Starke, R.D. et al. (2011) *Blood* 117, 1071-80.

**Species Reactivity**

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

**Western Blot Buffer**

**IMPORTANT:** For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

**Applications Key**

**W:** Western Blotting **IP:** Immunoprecipitation **IHC-P:** Immunohistochemistry (Paraffin)

**Cross-Reactivity Key**

**H:** Human

**Trademarks and Patents**

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

SignalStain is a registered trademark of Cell Signaling Technology, Inc.

XP is a registered trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit [cellsignal.com/trademarks](http://cellsignal.com/trademarks) for more information.

## Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.